MLICM
RGNX icon

Metropolitan Life Insurance Company (MetLife)’s Regenxbio RGNX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,284
Closed -$48.1K – 1669
2024
Q1 		$48.1K Hold
2,284
– – ﹤0.01% 1423
2023
Q4 		$41K Hold
2,284
– – ﹤0.01% 1550
2023
Q3 		$37.6K Hold
2,284
– – ﹤0.01% 1565
2023
Q2 		$45.7K Hold
2,284
– – ﹤0.01% 1472
2023
Q1 		$43.2K Sell
2,284
-414
-15% -$9.16K ﹤0.01% 1473
2022
Q4 		$61.2K Hold
2,698
– – ﹤0.01% 1345
2022
Q3 		$71.3K Hold
2,698
– – ﹤0.01% 1225
2022
Q2 		$66.6K Hold
2,698
– – ﹤0.01% 1318
2022
Q1 		$89.5K Sell
2,698
-8,295
-75% -$230K ﹤0.01% 1265
2021
Q4 		$359K Hold
10,993
– – ﹤0.01% 1632
2021
Q3 		$461K Hold
10,993
– – 0.01% 1518
2021
Q2 		$427K Buy
10,993
+525
+5% +$18.8K 0.01% 1617
2021
Q1 		$357K Sell
10,468
-72
-0.7% -$3.07K 0.01% 1627
2020
Q4 		$478K Hold
10,540
– – 0.01% 1378
2020
Q3 		$290K Hold
10,540
– – ﹤0.01% 1560
2020
Q2 		$388K Sell
10,540
-302
-3% -$11.3K 0.01% 1388
2020
Q1 		$351K Hold
10,842
– – 0.01% 1260
2019
Q4 		$444K Sell
10,842
-457
-4% -$18.1K 0.01% 1403
2019
Q3 		$402K Buy
11,299
+1,040
+10% +$42.1K 0.01% 1428
2019
Q2 		$527K Hold
10,259
– – 0.01% 1269
2019
Q1 		$588K Hold
10,259
– – 0.01% 1190
2018
Q4 		$430K Hold
10,259
– – 0.01% 1288
2018
Q3 		$775K Buy
10,259
+985
+11% +$71K 0.01% 1072
2018
Q2 		$665K Hold
9,274
– – 0.01% 1128
2018
Q1 		$277K Buy
9,274
+541
+6% +$15.7K ﹤0.01% 1674
2017
Q4 		$290K Sell
8,733
-9,767
-53% -$294K ﹤0.01% 1643
2017
Q3 		$610K Buy
18,500
+1,905
+11% +$42.9K ﹤0.01% 1553
2017
Q2 		$328K Hold
16,595
– – ﹤0.01% 1999
2017
Q1 		$320K Hold
16,595
– – ﹤0.01% 1958
2016
Q4 		$308K Hold
16,595
– – ﹤0.01% 2076
2016
Q3 		$232K Sell
16,595
-387
-2% -$4.27K ﹤0.01% 2245
2016
Q2 		$136K Buy
+16,982
New +$188K ﹤0.01% 2559

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RGNX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Regenxbio (RGNX) in Q2 2024, closing a stake of 2,284 shares — an estimated $48.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RGNX in Q2 2016 and held it in 32 quarters. The position peaked at $775K in Q3 2018. 181 funds tracked by Wall St. Rank hold RGNX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Regenxbio position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,284 Regenxbio shares in Q2 2024, an estimated $48.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Regenxbio in Q2 2016 and held it in 32 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Regenxbio position peaked at $775K in Q3 2018.
  • 181 funds tracked by Wall St. Rank held Regenxbio as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.